StockpollyBeta
Get App
Popularity #257
IOVA · NASDAQ · Biotechnology

Iovance Biotherapeutics (IOVA)

Commercializes TIL cell therapies for melanoma and other solid-tumor settings.

$10.38
vs last close−0.26 (−2.41%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue001315974496067877199
Cost of revenue44731404650571−101145
Gross profit−4−4−70192803661877054
114117111102108115121117161261151106
Research & development888780626872777975696264
27302634404344383536390
Selling & marketing00180003300000
General & administrative00804001100000
Other expenses00550000511565042
Operating income−118−121−118−102−89−87−121−114−95−73−81−52
3333410341213
Interest income3333410340710
Other non-operating income0−3−3−30−10−3−4−1−2−1−3
Income before tax−115−118−114−99−85−77−118−110−94−72−80−49
Income tax expense−1−2−1−1−22−22−20−1−1
Net income from continuing operations−114−116−113−97−84−79−116−112−91−72−79−47
Net income−114−116−113−97−84−79−116−112−91−72−79−47
EPS, basic−$0.46−$0.45−$0.42−$0.34−$0.28−$0.26−$0.36−$0.33−$0.25−$0.15−$0.19−$0.11
EPS, diluted−$0.46−$0.45−$0.42−$0.34−$0.28−$0.26−$0.36−$0.33−$0.25−$0.15−$0.19−$0.11
Weighted average shares, basic246256266285303305323335364407419450
Weighted average shares, diluted246256266285303305323335364407419450
EBITDA−108−108−104−88−78−65−107−98−85−68−71−39
Depreciation & amortization101010111112111294910
EBIT−118−118−114−99−89−77−118−110−94−72−80−49